Are fibroblast growth factor 23 concentrations in renal transplant patients different from non-transplanted chronic kidney disease patients?

Pediatric Transplantation

Volumn 16, Issue 1, 2012, Pages 73-77

  Filler, Guido ^a,b   Liu, Daisy ^a   Sharma, Ajay Parkash ^a   Grimmer, Joanne ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

fibroblast growth factor 23; hypophosphatemia; renal osteodystrophy; renal transplant; vitamin D levels

Indexed keywords

25 HYDROXYVITAMIN D; FIBROBLAST GROWTH FACTOR 23;

ADOLESCENT; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TRANSPLANTATION; MALE; PROTEIN BLOOD LEVEL; SCHOOL CHILD; VITAMIN BLOOD LEVEL;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPHOSPHATEMIA; INFANT; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 84856007182     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01613.x     Document Type: Article

References (20)

1. Feber J, Wong H, Geier P, Chaudry B, Filler G,. Complications of chronic kidney disease in children post-renal transplantation-A single center experience. Pediatr Transplant 2008: 12: 80-84.
2. Alon US,. Clinical practice: Fibroblast growth factor (FGF)23: A new hormone. Eur J Pediatr 2011: 170: 545-554.
3. Wesseling-Perry K, Tsai EW, Ettenger RB, Juppner H, Salusky IB,. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: A role for FGF-23? Nephrol Dial Transplant 2011: 26: 3779-3784.
4. Wolf M, Molnar MZ, Amaral AP, et al., Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011: 22: 956-966.
5. Trombetti A, Richert L, Hadaya K, et al., Early post-transplantation hypophosphatemia is associated with elevated FGF-23 levels. Eur J Endocrinol 2011: 164: 839-847.
6. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y,. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007: 7: 1193-1200. (Pubitemid 46643105)
7. Bhan I, Shah A, Holmes J, et al., Post-transplant hypophosphatemia: Tertiary 'hyper-phosphatoninism'? Kidney Int 2006: 70: 1486-1494. (Pubitemid 44527320)
8. Evenepoel P, Meijers BK, De Jonge H, et al., Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008: 3: 1829-1836.
9. Bacchetta J, Dubourg L, Harambat J, et al., The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 2010: 95: 1741-1748.
10. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A,. Cystatin C as a marker of GFR-History, indications, and future research. Clin Biochem 2005: 38: 1-8. (Pubitemid 39647648)
11. Akbari A, Hussain N, Karpinski J, Knoll GA,. Chronic kidney disease management: Comparison between renal transplant recipients and nontransplant patients with chronic kidney disease. Nephron Clin Pract 2007: 107: c7-c13. (Pubitemid 47360945)
12. Filler G, Liu D, Huang SH, Casier S, Chau LA, Madrenas J,. Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease. Clin Biochem 2011: 44: 435-437.
13. Filler G, Lepage N,. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol 2003: 18: 981-985. (Pubitemid 37236209)
14. Yamazaki Y, Okazaki R, Shibata M, et al., Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002: 87: 4957-4960. (Pubitemid 35316332)
15. Filler G, Witt I, Priem F, Ehrich JH, Jung K,. Are cystatin C and beta 2-microglobulin better markers than serum creatinine for prediction of a normal glomerular filtration rate in pediatric subjects? Clin Chem 1997: 43: 1077-1078.
16. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A,. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976: 58: 259-263.
17. Pande S, Ritter CS, Rothstein M, et al., FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006: 104: p23-p32.
18. Kawarazaki H, Shibagaki Y, Fukumoto S, et al., The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: A 1-year prospective observational study. Nephrol Dial Transplant 2011: 26: 2691-2695.
19. Cunningham J, Locatelli F, Rodriguez M,. Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011: 6: 913-921.
20. Matuszkiewicz-Rowinska J,. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of mineral and bone disorders in chronic kidney disease. Pol Arch Med Wewn 2010: 120: 300-306.